Abcellera Biologics/$ABCL
1D1W1MYTD1Y5YMAX
Capital at risk
About Abcellera Biologics
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
- Ticker
- $ABCL
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 562
- Headquarters
- Vancouver, Canada
- Website
- www.abcellera.com
ABCL Metrics
BasicAdvanced
$3.7B
-
-$0.55
1.19
-
Price and volume
Market cap
$3.7B
Beta
1.19
52-week high
$12.58
52-week low
$2.75
Average daily volume
8.2M
Financial strength
Current ratio
12.77
Quick ratio
11.226
Long term debt to equity
0.145
Total debt to equity
0.145
Profitability
EBITDA (TTM)
-199.96
Gross margin (TTM)
-198.88%
Net profit margin (TTM)
-248.84%
Operating margin (TTM)
-340.27%
Effective tax rate (TTM)
16.32%
Revenue per employee (TTM)
$120,000
Management effectiveness
Return on assets (TTM)
-10.39%
Return on equity (TTM)
-17.30%
Valuation
Price to revenue (TTM)
52.044
Price to book
3.9
Price to tangible book (TTM)
4.31
Price to free cash flow (TTM)
-28.777
Free cash flow yield (TTM)
-3.48%
Free cash flow per share (TTM)
-0.396
Growth
Revenue change (TTM)
101.27%
Earnings per share change (TTM)
-2.55%
3-year revenue growth (CAGR)
-23.04%
3-year earnings per share growth (CAGR)
27.97%
What the Analysts think about ABCL
Analyst ratings (Buy, Hold, Sell) for Abcellera Biologics stock.
Analyst projections of the future price of Abcellera Biologics stock.
Bulls say / Bears say
Jazz Pharmaceuticals signed a collaboration and license agreement with AbCellera to discover next-generation T-cell engaging multispecific antibodies, providing $56 million upfront for two initial programs plus $28 million for a third, and up to $792 million per program in milestones, validating AbCellera’s platform and adding non-dilutive capital (tradingview.com).
Subsequent to Q2, AbCellera entered a collaboration with Vertex Pharmaceuticals to research, develop, manufacture, and commercialize multispecific T-cell engagers for autoimmune diseases, receiving $28 million in upfront payments and potential milestone and royalty streams while limiting direct R&D spend (sec.gov).
As of June 30, 2026, AbCellera held over $565 million in cash and marketable securities plus $110 million in non-dilutive government funding, giving more than $675 million in available liquidity to fund pipeline advancement and upcoming data readouts (sec.gov)
Q2 2026 total revenue collapsed to $4.1 million from $17.1 million in Q2 2025, driven by research fee declines and licensing revenue plunging to $0.15 million from $10.45 million, undermining near-term top-line visibility (sec.gov).
Net loss widened to $55.4 million (–$0.18 per share) in Q2 2026 from $34.7 million (–$0.12 per share) a year earlier, reflecting intensifying cash burn before clinical milestones are achieved (sec.gov).
Research & Development expenses rose 17% year-over-year to $46.0 million in Q2 2026, further pressuring the company’s cash position given the lack of near-term revenue growth (sec.gov)
Data summarised monthly by Lightyear AI. Last updated on 6 Sept 2026.
ABCL Financial Performance
Revenues and expenses
ABCL Earnings Performance
Company profitability
Upcoming events
No upcoming events
ABCL News
AllArticlesVideos
AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026
Business Wire2 weeks ago
What'sGoing On With AbCellera Biologics Stock On Tuesday?
Benzinga3 weeks ago
AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants
Business Wire1 month ago
Funds containing ABCL
AllUSDEURGBP
Fund name | Fund size | $ABCL weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.28% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.28% |
iShares Healthcare Innovation£DRDR | £1B | 0.28% |
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.23% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.23% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.